ទំព័រដើម › មហារីកស្រទាប់ស្បែកស្តី › នូវយ៉ាក › New York City
ការសាកល្បងគ្លីនិកសម្រាប់ មហារីកស្រទាប់ស្បែកស្តី នៅក្នុង New York City, NY
ការសិក្សាចំនួន 52 សម្រាប់ មហារីកស្រទាប់ស្បែកស្តី កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ New York City (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Mount Sinai Chelsea, New York
- Mount Sinai West, New York
- Mount Sinai Hospital, New York
- និង 3 ទៀត
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
កំពុងជ្រើសរើសដំណាក់កាល 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of PHST001 in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Mount Sinai, New York
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 2
- Memorial Sloan Kettering Hospital, New York
Study of AVZO-021 in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Avenzo Therapeutics Recruiting Site, New York
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
កំពុងជ្រើសរើស
- Memorial Sloan Kettering Cancer Center, New York
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Research Site, New York
- Research Site, New York
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
កំពុងជ្រើសរើសដំណាក់កាល 2
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
កំពុងជ្រើសរើសដំណាក់កាល 1
- New York University (NYU) Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Memorial Sloan Kettering Cancer Center (MSKCC), New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
កំពុងជ្រើសរើសដំណាក់កាល 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- NYU Langone Health, New York
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6004), New York
- Memorial Sloan Kettering Cancer Center ( Site 6053), New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- NYU Laura and Isaac Perlmutter Cancer Center - 34th Street, New York
- Perlmutter CC NYU Langone LI, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Memorial Sloan Kettering Cancer Center, New York
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Research Site, New York
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Icahn School of Medicine at Mount Sinai, New York
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
កំពុងជ្រើសរើសដំណាក់កាល 2
- Laura & Isaac Perlmutter Cancer Center, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Mount Sinai Health System, New York
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
កំពុងជ្រើសរើសដំណាក់កាល 1
- Memorial Sloan Kettering Cancer Center, New York
FOG-001 in Locally Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Memorial Sloan Kettering Cancer Center, New York
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- NYP/Weill Cornell Medicine, New York
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
កំពុងជ្រើសរើសដំណាក់កាល 2
- Memorial Sloan Kettering Cancer Center, New York
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
កំពុងជ្រើសរើសដំណាក់កាល 2
- Memorial Sloan Kettering Cancer Center, New York
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- New York University Langone Health, New York
- ICHAN School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
កំពុងជ្រើសរើសដំណាក់កាលដំបូង ១
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4175408 in Participants With Advanced Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Columbia University, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of a Weight Loss Intervention in People With Endometrial Cancer
កំពុងជ្រើសរើសដំណាក់កាលដំបូង ១
- Memorial Sloan Kettering Cancer Center, New York
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Multiparametric Ultrasound Imaging (mpUS) for People With Endometrial Cancer
កំពុងជ្រើសរើស
- Memorial Sloan Kettering Cancer Center, New York
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Memorial Sloan Kettering Cancer Center, New York
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Memorial Sloan Kettering Cancer Center, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massive Bio SYNERGY-AI site, New York
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NYU Langone Health, New York
Comprehensive Outcomes for After Cancer Health
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Memorial Sloan Kettering Cancer Center, New York
ការសាកល្បងសម្រាប់ មហារីកស្រទាប់ស្បែកស្តី នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 68
- Boston, MAការសិក្សា 50
- Arlington, VAការសិក្សា 39
- Nashville, TNការសិក្សា 38
- Los Angeles, CAការសិក្សា 34
- St. Louis, MOការសិក្សា 29
- Philadelphia, PAការសិក្សា 28
- San Antonio, TXការសិក្សា 27
- Columbus, OHការសិក្សា 25
- Oklahoma City, OKការសិក្សា 25
- Chicago, ILការសិក្សា 25
- Queens, NYការសិក្សា 25
ការសិក្សាផ្សេងទៀតនៅក្នុង New York City
- មហារីកទ្រូងការសិក្សា 136
- Non-Small Cell Lung Cancerការសិក្សា 121
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 109
- មហារីកតូចការសិក្សា 103
- មហារីកដែលរីករាលដាលការសិក្សា 93
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 78
- មហារីកស៊ុតការសិក្សា 69
- មហារីកសួតការសិក្សា 60
- ជំងឺ Multiple Myelomaការសិក្សា 60
- មហារីកតំបក់ការសិក្សា 60
- ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ការសិក្សា 51
- បេះដូងខ្សោយការសិក្សា 51
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។